Skip to main content
Evidence Snapshot

Bacillus subtilis

CHEMBL359 ORGANISM Bacillus subtilis
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:31:20Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL359
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Bacillus subtilis as ChEMBL target CHEMBL359. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Bacillus subtilis
ORGANISM · Bacillus subtilis
As of 2026-09-13
ChEMBL target ID
CHEMBL359
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Bacillus subtilis matters

As of 2026-09-13

Bacillus subtilis is reviewed as Bacillus subtilis; the current evidence base includes 13 approved drugs, 23488 compounds, and 3838 assays, with lead potency reaching pChEMBL 8.4.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 13 approved drugs, 23488 compounds, and 3838 assays for this target. The dominant activity type is IC50. CHEMBL4175069 is the current potency anchor at pChEMBL 8.4.

Use CHEMBL4175069 as the tractability anchor when discussing potency (pChEMBL 8.4).

Activity source · ChEMBL 36 via Core Engine
13 approved pChEMBL 8.4
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Bacillus subtilis matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

23488
Total Compounds
3838
Total Assays
13
Approved Drugs
IC50: 602.0, EC50: 37.0, KD: 10.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4175069
 8.4 IC50 —
No preferred name
CHEMBL4164425
 8.2 IC50 —
No preferred name
CHEMBL4176131
 8.0 IC50 —
No preferred name
CHEMBL4164850
 8.0 IC50 —
No preferred name
CHEMBL4163914
 7.9 IC50 —

Approved Drugs

Structure Compound First Approval
CIPROFLOXACIN
CHEMBL8
 1987
MITOMYCIN
CHEMBL105
 1981
AMOXICILLIN
CHEMBL1082
 1974
KANAMYCIN
CHEMBL1384
 1973
TRIMETHOPRIM
CHEMBL22
 1973
CEPHALEXIN ANHYDROUS
CHEMBL1727
 1971
AMPICILLIN
CHEMBL174
 1965
ERYTHROMYCIN
CHEMBL532
 1964
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:31:20Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL359